ArticleLaryngoscope investigative otolaryngology2026
Oropharyngeal Dysphagia Assessment in Behçet Disease Using EAT-10 and Fiberoptic Endoscopic Evaluation of Swallowing.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To provide a preliminary symptom-based and standardized single-consistency FEES screening assessment of swallowing in adults with Behçet disease using the Eating Assessment Tool-10 (EAT-10) and fiberoptic endoscopic evaluation of swallowing (FEES). Methods: This single-center cross-sectional observational study with prospective enrollment was conducted between September 2022 and March 2024. Adult patients with Behçet disease completed the EAT-10 and underwent FEES using an IDDSI level 3 moderately thick bolus (yellow pudding). FEES outcomes were scored using the Penetration-Aspiration Scale (PAS), Yale Pharyngeal Residue Severity Rating Scale for vallecular and pyriform sinus residue (YPRSRS-V and YPRSRS-P), Functional Outcome Swallowing Scale (FOSS), and Functional Oral Intake Scale (FOIS). Results: Twenty-seven patients were included (20 women, 7 men). Mean age was 45.7 ± 8.0 years and mean disease duration was 10.4 ± 7.6 years. The mean EAT-10 score was 4.0 ± 6.6, and 10 patients (37.0%) had an abnormal EAT-10 score (≥ 3). With the tested IDDSI level 3 bolus, PAS was ≥ 2 in 1 patient (3.7%). Vallecular residue (YPRSRS-V ≥ 2) was observed in 5 patients (18.5%) and pyriform sinus residue (YPRSRS- Conclusion: In Behçet disease, patient-reported swallowing complaints were relatively common, whereas objective FEES evidence of penetration or aspiration was uncommon. Pharyngeal residue, particularly vallecular residue, was more frequent than airway invasion under this standardized bolus condition. EAT-10-based screening with selective FEES may help identify patients who may benefit from multidisciplinary swallowing evaluation. Level of Evidence: 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.